Research

Metastatic relapse remains a major challenge in oncology, driven by the unpredictable fate of disseminated cancer cells. While some rapidly form aggressive secondary tumors, others persist in a dormant or slow-cycling state for years before reactivating. This project aims to uncover the factors that determine these diverse outcomes—whether driven by intrinsic properties like metabolic autonomy or influenced by cues from the surrounding microenvironment. We will investigate cancer cell metabolic dependencies, focusing on nutrient transporters, mitochondrial function, and metabolic reprogramming. Using gene perturbation, metabolomics, isotope tracing, and in vivo models, we aim to dissect how these factors shape cell behavior and fate. The insights gained could lead to new biomarkers and therapeutic strategies to prevent relapse and better manage metastatic disease across cancer types. 

Cervical cancer remains a major public health challenge in India, largely due to late-stage diagnoses and metastatic progression, which complicate treatment and increase mortality. Although HPV vaccines and screening programs are available, their adoption is limited, especially in rural areas due to cultural stigma, lack of awareness, and inadequate healthcare infrastructure. Current screening methods are also invasive and socially uncomfortable, reducing participation and offering limited insight into metastatic disease. This project proposes a non-invasive, urine-based strategy for the early and metastatic detection of cervical cancer using metabolomics. By analyzing urine samples to identify metabolic biomarkers linked to disease progression, we aim to develop a culturally acceptable and patient-friendly diagnostic approach. The ultimate goal is to create a portable, low-cost diagnostic tool suited for resource-limited settings, with potential scalability for use in other cancers and diseases.